Search results for "Non small cell"
showing 8 items of 68 documents
Time to give a rest to cetuximab in the treatment of advanced non-small cell lung carcinoma?
2018
Chemotherapy with a platinum-based doublet has long been the cornerstone of the treatment for advanced non-small cell lung carcinoma (NSCLC) (1). Since the early 2000s, several driver gene mutations and translocations have been discovered, giving rise to the possibilities of targeted therapies (2-4).
Quelle place reste-t-il pour la chirurgie dans les cancers bronchiques de stade IIIA-N2 ?
2015
Resume Introduction Le cancer bronchique non a petites cellules (CBNPC) demeure un probleme de sante majeur, avec une survie globale a 5 ans des stades IIIA de l’ordre de 25 %. La prise en charge chirurgicale des CBNPC de stade IIIA demeure cependant controversee. Nous avons donc evalue les differentes strategies de prise en charge des CBNPC de stade IIIA-N2. Methodes De janvier 1990 a decembre 2013, les essais controles randomises evaluant la survie des patients traites par chimiotherapie d’induction suivie d’une resection chirurgicale vs chirurgie seule, et ceux evaluant la survie des patients traites par radio- ou chimiotherapie d’induction suivie d’une resection chirurgicale vs la combi…
MA04.03 Lung Tumorspheres Characterization Reveals Cancer Stem-Like Cells Potential Targets and Prognostic Markers in Non-Small Cell Lung Cancer
2019
Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?
2020
Abstract Introduction Non-small-cell lung cancer (NSCLC) is one of the most common and deadly cancers. Several molecular drivers of oncogene addiction are now known to be strong predictive biomarkers for target therapies. Advances in large Next Generation Sequencing (LNGS) have improved the ability to detect potentially targetable mutations. However, the integration of LNGS into clinical management in an individualized manner remains challenging. Methods In this single-center observational study we included all patients with advanced NSCLC who underwent LNGS. Somatic and germline exome analysis was performed with a restriction on 323 cancer related genes. Variants were classified and Molecu…
165P Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small c…
2021
P1.05-013 Lung Tumorspheres as a Platform for Testing New Therapeutic Strategies in Non-Small Cell Lung Cancer
2017
167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials
2021
Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
2018
In the N Engl J Med , Soria and colleagues have recently reported the results of the phase III randomized FLAURA trial (1), comparing osimertinib with first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib or erlotinib in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) and activating EGFR -mutations.